Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial

Trial profile of patients. One patient (0.02%) stopped skin ulcer treatment with SR-0379 at day 23 and was withdrawn at day 24. The patient was judged to be included in the FAS for the efficiency and safety evaluatio